Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

QIAGEN Introduces CE-marked Molecular Assay for the Cancer Biomarker K-ras

Published: Tuesday, November 11, 2008
Last Updated: Tuesday, November 11, 2008
Bookmark and Share
Pyrosequencing-based molecular test can detect and profile genetic mutations to predict responses to EGFR inhibitor therapies in colorectal cancer patients.

QIAGEN N.V. has announced the launch of a new test to determine mutations of the K-ras gene. The K-ras gene is mutated in between 35 percent and 45 percent of metastatic colorectal cancer (CRC) patients.

Studies have shown that K-ras testing can better define which CRC patients will benefit from treatment with epidermal growth factor receptor (EGFR) inhibiting monoclonal antibodies, such as Amgen’s Vectibix® (panitumumab) and Imclone/Bristol-Myers Squibb’s Erbitux® (cetuximab).

QIAGEN’s new “PyroMark Q24 K-ras Assay-Kit” is CE-marked for use in second-line treatment of metastatic CRC together with Erbitux or Vectibix and will be available near the beginning of 2009. QIAGEN intends to launch this assay for in vitro diagnostic use in the United States as well.

QIAGEN’s new “PyroMark Q24 K-ras Assay-Kit” is able to detect all major and minor known mutations in the K-ras codons 12, 13 and 61, and, in addition, allows the discovery of new mutations as well. This assay is the first molecular assay QIAGEN is launching based on Pyrosequencing, a fundamental technology for short-length, high resolution sequence analysis and quantification. QIAGEN acquired the technology and the associated business in October 2008 from Biotage.

The market for K-ras testing has seen strong momentum over the last months. A number of recently published studies, including a large multinational prospective study conducted by the Belgian University in Leuven, suggested that the K-ras mutation status is a prognostic biomarker predicting the outcome of EGFR therapies.

In this study, approximately 40% of all CRC-patients had mutated K-ras genes. The trial data indicated that such patients will not benefit from, and in some cases even experience negative reactions to EGFR antibodies, while patients without specific mutations are likely to benefit from this drug treatment.

In response to these studies, European regulators adopted the indication for Vectibix (panitumumab) to include only patients whose tumors carry the unmutated K-ras gene.

Earlier this month, the U.S. National Comprehensive Cancer Network (NCCN) issued new guidelines for treatment of CRC which recommended that only patients with tumors characterized by the unmutated K-ras gene shall be treated with EGFR drugs. This organization of 21 cancer centres furthermore recommended that oncologists should generally determine the K-ras gene status of all patients diagnosed with CRC prior to any treatment.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Both products receive 510(k) clearance for in vitro diagnostic use in the U.S..
Tuesday, April 17, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN and Genome Diagnostics Expands Partnership to Develop Tests for Applications in Prevention and Personalized Healthcare
Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases.
Friday, June 18, 2010
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos